Does B Vitamin Supplementation Decrease Homocysteine Concentrations in Newborns

R

Radboud University Medical Center

Status and phase

Completed
Phase 1

Conditions

Mild Hyperhomocysteinemia

Treatments

Drug: 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)

Study type

Interventional

Funder types

Other

Identifiers

NCT00877227
0010-0237

Details and patient eligibility

About

The purpose of this study is to determine whether supplementation with folinic acid, a B vitamin, lowers the concentrations of total homocysteine in newborns. Increased homocysteine concentrations are associated with an increased risk of cerebrovascular accidents in adult, children and newborns. These increased concentrations can easily and safely be lowered by folic acid in adults.

Full description

The incidence of cerebrovascular accidents (CVA) occurring perinatally is relatively high and aspects of the multifactorial pathophysiology remain unclear. Elevated homocysteine concentrations are shown to be associated with an increased risk for CVA in newborns. We want to study the possible homocysteine lowering effect of folinic acid in newborns. We will include newborns in our prospective randomized folinic acid intervention study from patients admitted to our Neonatal Intensive Care Unit. We will measure total homocysteine (tHcy) and folate concentrations at three time points. The intervention group will be treated with folinic acid (70 µg/kg/day) for two weeks.

Enrollment

37 patients

Sex

All

Ages

Under 2 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • admitted at our NICU

Exclusion criteria

  • midline defects
  • Extracorporeal membrane oxygenation (ECMO) treatment
  • blood transfusion
  • overt renal failure

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

37 participants in 2 patient groups

folinic acid
Experimental group
Description:
Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
Treatment:
Drug: 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)
2
No Intervention group
Description:
control subjects admitted at the Neonatal Intensive Care Unit (NICU)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems